[go: up one dir, main page]

NO20043418L - Stabiliserte adenovirusformuleringer - Google Patents

Stabiliserte adenovirusformuleringer

Info

Publication number
NO20043418L
NO20043418L NO20043418A NO20043418A NO20043418L NO 20043418 L NO20043418 L NO 20043418L NO 20043418 A NO20043418 A NO 20043418A NO 20043418 A NO20043418 A NO 20043418A NO 20043418 L NO20043418 L NO 20043418L
Authority
NO
Norway
Prior art keywords
adenovirus formulations
stabilized
stabilized adenovirus
formulations
adenovirus
Prior art date
Application number
NO20043418A
Other languages
English (en)
Inventor
Erno Pungor
Elisabeth Lehmberg
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20043418L publication Critical patent/NO20043418L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
NO20043418A 2002-01-18 2004-08-17 Stabiliserte adenovirusformuleringer NO20043418L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34922202P 2002-01-18 2002-01-18
PCT/US2003/001055 WO2003061708A1 (en) 2002-01-18 2003-01-15 Stabilized formulations of adenovirus

Publications (1)

Publication Number Publication Date
NO20043418L true NO20043418L (no) 2004-08-17

Family

ID=27613260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043418A NO20043418L (no) 2002-01-18 2004-08-17 Stabiliserte adenovirusformuleringer

Country Status (18)

Country Link
US (1) US20030232018A1 (no)
EP (1) EP1465664A1 (no)
JP (1) JP2005515245A (no)
KR (1) KR20040077878A (no)
CN (1) CN1617745A (no)
AR (1) AR038153A1 (no)
BR (1) BR0306925A (no)
CA (1) CA2469721A1 (no)
IL (1) IL162404A0 (no)
MX (1) MXPA04006995A (no)
NO (1) NO20043418L (no)
PE (1) PE20030851A1 (no)
PL (1) PL371261A1 (no)
RU (1) RU2004125283A (no)
TW (1) TW200307750A (no)
UY (1) UY27614A1 (no)
WO (1) WO2003061708A1 (no)
ZA (1) ZA200406547B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
EA201390810A1 (ru) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
ES2630012T3 (es) 2010-12-02 2017-08-17 Oncolytics Biotech Inc. Formulaciones virales liofilizadas
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
SG11201508567XA (en) 2013-04-25 2015-11-27 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CN107466324B (zh) 2015-04-14 2022-01-14 扬森疫苗与预防公司 具有双向启动子的表达两种转基因的重组腺病毒
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
HK1254838A1 (zh) * 2015-10-06 2019-07-26 Janssen Vaccines & Prevention B.V. 用於预防生物制品的塑料诱导降解的方法
CN109069612A (zh) 2016-04-05 2018-12-21 扬森疫苗与预防公司 针对rsv的疫苗
EP3808374A1 (en) 2016-04-05 2021-04-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection
BR112018072865A2 (pt) 2016-05-12 2019-04-30 Janssen Vaccines & Prevention B.V. promotor bidirecional potente e equilibrado
PE20190110A1 (es) 2016-05-30 2019-01-15 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
CN110268061B (zh) 2017-02-09 2024-07-16 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
BR112020004143A2 (pt) 2017-09-15 2020-09-01 Janssen Vaccines & Prevention B.V. método para a indução segura de imunidade contra vírus sincicial respiratório (rsv)
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
PH12021550974A1 (en) 2018-11-13 2022-05-02 Janssen Vaccines & Prevention Bv Stablized pre-fusion rsv f proteins
CN116096732A (zh) 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
CN115354068A (zh) * 2022-09-16 2022-11-18 武汉中帜生物科技股份有限公司 一种灭活型病毒保存液及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310924T3 (es) * 1993-07-13 2009-01-16 Centelion Vectores adenovirales defectivos y utilizacion en terapia genica.
FR2718150B1 (fr) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
IL127692A0 (en) * 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
CA2723040A1 (en) * 1998-02-17 1999-08-19 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
PT1150712E (pt) * 1999-02-05 2008-12-22 Merck & Co Inc Formulações para a vacina do vírus do papiloma humano
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤

Also Published As

Publication number Publication date
PE20030851A1 (es) 2004-01-01
CN1617745A (zh) 2005-05-18
JP2005515245A (ja) 2005-05-26
EP1465664A1 (en) 2004-10-13
BR0306925A (pt) 2004-11-09
US20030232018A1 (en) 2003-12-18
ZA200406547B (en) 2006-06-24
WO2003061708A1 (en) 2003-07-31
AR038153A1 (es) 2004-12-29
MXPA04006995A (es) 2005-07-13
RU2004125283A (ru) 2005-06-10
PL371261A1 (en) 2005-06-13
CA2469721A1 (en) 2003-07-31
KR20040077878A (ko) 2004-09-07
UY27614A1 (es) 2003-08-29
TW200307750A (en) 2003-12-16
IL162404A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
NO20043418L (no) Stabiliserte adenovirusformuleringer
DK3536344T3 (da) Superfin formoterolformulering
PT1501534E (pt) Formulacoes farmaceuticas
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
NO20052635D0 (no) Kontrollert frigivelsesdepot formuleringer
FR2842416B1 (fr) Composition cosmetique
FR2842417B1 (fr) Composition cosmetique
EP1653935A4 (en) INFLAMMATORY FORMULATIONS
DK3473251T3 (da) Nikotin-cellulose-kombination
NO20033556L (no) Farmasöytiske formuleringer
DE60231431D1 (de) Ement
DK3354263T3 (da) Tørpulverformuleringer
DK1421841T3 (da) Mejetærsker
EP1559433A4 (en) STABILIZED COMPOSITION
DE60209252D1 (de) Stabilisierte polymerzusammensetzung
DE10393374D2 (de) Zusammensetzung
DE60322720D1 (de) Feste formulierungen enthaltend eine indolinon verbindung
IS8309A (is) Lyfjablöndur
DK1561472T3 (da) Faststofsammensætning
DK1539089T3 (da) Reducerede aerosol-genererende formuleringer
DE60218346D1 (de) Stabilisierte topische brivudin-formulierungen
SE0500163L (sv) Sammansättning
IS7500A (is) thurrdufts samsetningar
FI20020313A7 (fi) Uudet tärkkelyskoostumukset
ITMI20011532A0 (it) Cosmetico solido

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application